Sentiment Summary
Recent Events
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
Q1 2026 earnings release and conference call scheduled.
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
Abbott Laboratories is scheduled to announce its first-quarter 2026 financial results before the market opens on April 16, 2026, scheduled.
First quarter 2026 earnings release and conference call scheduled.
FDA decision for orforglipron, a once-daily oral GLP-1 drug for obesity, is expected. Approval would represent a major expansion of Lilly's obesity franchise into a more convenient oral treatment.
Ex-dividend date for a quarterly dividend of $0.63 per share, payable on May 1, 2026.
Board meeting to be held on March 30, 2026, to approve and announce the annual results for the year ended December 31, 2025. High importance estimated as annual results typically result in ≥10% price impact, scheduled.
Announced full-year 2025 results on 2026-03-29; analysts forecast revenue up 22.6% and net profit up 27.1%. High importance estimated due to strong growth expected.
Announced positive results from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), meeting its primary endpoint on March 29, 2026.
Announced positive detailed results from the Phase 2 CADENCE trial for WINREVAIR™ (sotatercept-csrk) on 2026-03-29, meeting the primary endpoint; estimated to have a medium impact of ~5% due to positive clinical data.
Amgen announced on March 28, 2026, new Phase 3 trial data for Repatha showing reduced cardiovascular risk; medium impact (>=5%) estimated due to significant clinical data, expected.
Presented positive new long-term 52-week data for ICOTYDE™ at the AAD Annual Meeting on March 28, 2026; moderate impact expected as data supports long-term efficacy and safety.
Presented positive Phase 3b data showing that combining Taltz and Zepbound was superior to Taltz alone for adults with both psoriatic arthritis and obesity.
Announced FY2025 results, reporting revenue of approximately 3.25 billion RMB (89.4% YoY increase) and a net profit of approximately 710 million RMB, achieving a turnaround; High importance reflects the significant financial recovery likely to cause >10% price impact.
The European Medicines Agency's (EMA) CHMP issued a positive opinion on March 27, 2026, recommending marketing authorization for tarlatamab (Imdelltra); high impact (>=10%) estimated due to major regulatory milestone, expected.
Received drug registration approval from China's NMPA on 2026-03-27 for the third indication of Xinyue®; Medium importance estimated as new indications drive growth expected.
The special designation 'U' (unprofitable) was officially removed from the company's A-share stock on March 27, 2026, following its achievement of full-year profitability.
The company repurchased 5.35 million of its own shares for a total of HKD 31.44 million on 2026-03-27, which is estimated to have a low price impact (≥1%) as it is a standard buyback.
Received European approval on March 27, 2026, for a label update to allow self-administration of DARZALEX® subcutaneous formulation; low impact expected from incremental label expansion.
Akeso announced its full-year 2025 financial results on March 26, 2026. Revenue grew 43.9% year-over-year to RMB 3.06 billion, but the net loss widened to RMB 1.11 billion, missing analyst expectations. High importance estimated due to potential for >10% price impact from significant earnings miss, expected.
Announced FY2025 results: Revenue rose 10.3% to RMB 31.83B, and adjusted net profit rose 31.4% to RMB 4.54B. A final dividend of HKD 0.05 per share was proposed, which is estimated to have a medium price impact (≥5%) due to strong profit growth.
Innovent Biologics announced its 2025 annual results, reporting total revenue of RMB 13.04 billion, a 38.4% YoY increase. The company achieved its first full-year net profit of RMB 814 million, a significant turnaround from a net loss in 2024. The stock surged over 7% following the announcement.
Announced full-year 2025 financial results, reporting total revenue of RMB 574.1 million. Sales of core product Olverembatinib grew 81% YoY to RMB 435.3 million, and newly launched Lisaftoclax generated RMB 70.6 million. However, the net loss for the period widened to RMB 1.24 billion. Medium importance estimated due to significant revenue growth in core products; scheduled.
Full-year 2025 results announcement on March 25, 2026, reporting revenue of RMB 26.01 billion (-10.4% YoY) and net profit of RMB 3.88 billion (-10.3% YoY); high importance reflects the expected significant negative market reaction to declining profitability scheduled.
Announced strong full-year 2025 financial results on March 25, 2026. Revenue grew 13.02% YoY to RMB 31.63 billion, and net profit attributable to shareholders increased 21.69% YoY to RMB 7.71 billion, driven by a 26.09% increase in innovative drug sales.
InnoCare Pharma announced its FY2025 results on March 25, 2026, reporting its first-ever annual profit of RMB 644 million and revenue growth of 135.3% year-over-year.
On March 25, 2026, Akeso announced it received NMPA clearance to initiate Phase II clinical trials for two ADCs, AK146D1 and AK138D1, advancing its 'IO 2.0 + ADC 2.0' strategy. Medium importance estimated due to potential for >5% price impact from clinical progress, scheduled.
Announced audited annual results for the year ended December 31, 2025. Revenue increased by 16.7% year-over-year to RMB 21.8 billion, and adjusted net profit rose by 22.0% year-over-year to RMB 6.6 billion.
Announced that the Phase 3 STAR study of its eye disease drug Efdamrofusp Alfa (IBI302) met its primary endpoint, demonstrating non-inferiority to Eylea for treating neovascular age-related macular degeneration (nAMD). The drug also showed potential for less frequent dosing. [Estimate: Medium importance due to significant Phase 3 clinical milestone].
Announcement of the first patient dosed in a Phase III clinical study for Anbenitamab (KN026) on March 24, 2026; low importance as clinical milestones generally have limited immediate price impact scheduled.
Following the FY2025 earnings release, analysts revised their consensus price target for Giant Biogene downwards by 13% to HK$46.13 on March 24, 2026, forecasted.
Announced on 2026-03-24 that the IND application for SKB103 was approved by the NMPA for advanced solid tumors; Low importance estimated as an early-stage clinical milestone expected.
Regeneron and Sanofi announced that Dupixent (dupilumab) was approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid (BP) on 2026-03-24.
Announced full-year 2025 results on March 23, 2026, with revenue increasing 46.7% YoY to RMB 5.944 billion and adjusted net profit rising 69.9% YoY to RMB 1.559 billion.
Announced full-year 2025 results on March 23, 2026, with revenue increasing 15.8% YoY to RMB 45.46 billion and net profit attributable to shareholders rising 102.65% to RMB 19.15 billion, partly due to a one-time gain from a stake sale.
Announced fiscal year 2025 results on 2026-03-23, reporting revenue of RMB 2.06 billion (+6.5%) and a net loss of RMB 382 million (+43.2%); High importance estimated due to significant loss widening expected.
Provided 2026 full-year guidance on March 23, 2026, where the company forecasts revenue between RMB 51.3 billion and RMB 53.0 billion, representing 18% to 22% growth for continuing operations, forecasted.
Announced that its antibody-drug conjugate (ADC) Disitamab Vedotin was approved by China's NMPA for its 4th indication: treatment of HER2-low expressing breast cancer with liver metastases; Medium importance reflects the positive regulatory milestone likely to cause >5% price impact.
Pfizer and partner Valneva announced positive topline results from the Phase 3 trial of their Lyme disease vaccine candidate (PF-07307405), showing over 70% efficacy. The companies plan to seek regulatory approval.
Announced that the first participant has been dosed in a Phase 3 clinical study of IBI128 (Tigulixostat), a treatment for gout, in China. [Estimate: Low importance as initial dosing in a Phase 3 trial is a routine update].